Hypertension Diagnostics
Announces FY 2003 Results

ST. PAUL, MN September 29, 2003 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the fiscal year ended June 30, 2003.

 

  
Revenue for the fiscal year ended June 30, 2003 totaled $775,336 compared to $549,198 in the prior year ended June 30, 2002. The Company incurred a net loss of $3,802,381 for fiscal year 2003 or $.45 per share compared with a net loss of $6,369,666 for fiscal year 2002 or $1.07 per share. Included in the net loss for fiscal year 2003 are the following non-cash expense charges: $400,000 for the fair value of common stock and warrants issued to a firm for investor communications and public relations consulting services; $165,136 in amortized debt discount relating to the private placement of convertible debt ; and $850,000 in connection with the creation of an inventory reserve allowance.

On August 28, 2003, the Company completed a private placement offering (the “Offering”) to a group of investors led by Mark N. Schwartz. Gross proceeds from this offering were approximately $2,300,000. The offering involved the sale of units with each unit comprised of shares of the Company’s Series A Convertible Preferred Stock, Common Stock and warrants to acquire both Common and Series A Convertible Preferred Stock. The Company sold a total of 585,980 Units. Simultaneously with the closing of the Offering, the Company closed a transaction with its 8% Noteholders pursuant to which they tendered their notes to the Company along with accrued interest thereon totaling $529,980 for 3,238,767 shares of the Company’s common stock.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2002 Annual Report on Form 10-KSB, as amended, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

View PDF file: FY 2003 Results

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
  
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Return to the Main HDI Newsroom

   

Back to Top

 

 

     

Copyright © 2010 Hypertension Diagnostics, Inc
Last revised Wednesday June 23, 2010
HDI Legal Information